金凯生科(301509) - 2024 Q4 - 年度业绩预告

Financial Performance Outlook - The company expects a net profit attributable to shareholders of between 38 million and 45 million CNY for 2024, representing a decline of 74.07% to 78.11% compared to the previous year's profit of 173.57 million CNY[2] - The net profit after deducting non-recurring gains and losses is projected to be between 17 million and 24 million CNY, indicating a decrease of 85.70% to 89.87% from last year's profit of 167.84 million CNY[2] Factors Affecting Performance - The significant decline in performance is attributed to reduced orders in the pharmaceutical business due to international trade environment factors and fluctuations in orders from major clients[4]